Hepatocellular carcinoma (HCC) is usually refractory to the available treatments. For cancer gene therapy purposes, real-time imaging of therapeutic gene expression is of great importance because there are multiple factors that modulate the therapeutic gene expression in a complex tumor microenvironment. As a consequence, multiple doses of therapeutic viral vectors may be required for improved efficacy. In the present study, the luciferase reporter gene and the yeast cytosine deaminase (yCD) genes were bicistronically expressed using the foot-and-mouth disease virus 2A peptide under the regulation of the cytomegalovirus (CMV) promoter. The effectiveness of the yCD/5-FC (5-fluorocytosine) killing efficacy mediated by the herpes simplex virus type 1 (HSV-1) amplicon viral vector was shown using HCC and non-HCC cell lines in vitro. In addition, in vivo experiment also showed tumor regression of a primary HCC 26-1004 tumor xenograft in tumor expressing high levels of the yCD gene (as determined by noninvasive imaging) after intratumoral injection of 1.5Â10 6 TU HGCX-L2C HSV-1 amplicon viral vector and 5-FC administration. The HSV-1 amplicon viral vector coupled with the yCD/5-FC prodrug activated suicide gene could potentially be of use in clinical gene therapy for HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. 1 Curative treatment of HCC includes surgical resection and liver transplantation. 2 However, only 10-20% of HCC patients undergo surgery because of physically inaccessible tumors, poor liver function or advanced stage of the disease. 3 Even after the tumors have been successfully removed, the recurrent rate of HCC in the remnant cirrhotic liver remains as high as 70%. 4 Recently, Tian et al. 5 reported that multiple hepatic arterial injections of a recombinant adenovirus (Ad) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization can prolong the overall survival of patients with unresectable HCC. However, many of the vector-based clinical trials rely on the crude assessment of patient survival data as an indirect correlation to the possible functionality of the viruses. In the present study, by exploiting advances made in bioimaging technology during the recent years, we hope to provide a method for the precise monitoring of the therapeutic gene expression conferred by the viral vectors in patient-derived HCC xenografts.
Bioluminescence and fluorescence imaging has become a useful tool in cancer and gene therapy research. It can be used for determining the transduction efficiency, promoter activity, growth kinetics of tumor xenograft mouse models and various other applications. [6] [7] [8] Using engineered lentiviral vectors co-expressing the mutant epidermal growth factor receptor variant III and reporters consisting of green fluorescent and Renilla luciferase proteins, a group of researchers showed that there is a direct correlation between epidermal growth factor receptor expression and glioma cell proliferation in the initial stages of glioma progression. 9 Winkeler et al. 10 have reported the feasibility of monitoring the dynamics of regulated gene expression mediated by herpes simplex virus type 1 (HSV-1) amplicon vectors after in vivo transduction in experimental gliomas. All of these studies require co-expression of reporter gene with gene of interest. This can be achieved by two coordinately acting promoters, [10] [11] [12] gene fusion 13 and by including proteolytic cleavable sites such as fusagene or translational linkers such as the internal ribosome entry site (IRES) or self-processing peptides. 14 Over the last 10 years, the IRES element has been the most common way to express multiple genes in a single vector. However, IRES derived from different sources varied in term of efficiencies 15 and the expression of the downstream coding sequence is often translated at much lower levels (about 10-50%) when compared with the upstream sequence. 16 In view of the imbalance of protein expression that makes it difficult to predict the level of expression of the transgene, foot-and-mouth disease virus (FMDV) 2A peptide sequence, which is at least five times shorter than the IRES sequence and confer efficient bicistronic gene expression to similar protein levels, is employed. 17 In fact, multicistronic gene expression of up to four genes has been successfully mediated by the 2A peptide sequence. 18 Given that most current treatment procedure of cancer consists of combination therapy, which provides enhanced efficacy and safety, it is therefore of relevance to evaluate transgene expression using the 2A peptide sequence. The gained information can assist us in designing safer and more effective treatment regimes with the use of viral vectors.
Yeast cytosine deaminase (yCD) is a prodrug activated suicide gene that has shown potential as a therapeutic agent for HCC. 19 With the presence of prodrug 5-fluorocytosine (5-FC), yCD can convert 5-FC into highly toxic chemotherapeutic compound 5-FU, and has been one of the standard treatment for advanced colorectal and HCC for several years. 20 5-FU is first metabolized to 5-fluoro uridine monophosphate (5-fluoro-UMP), which is subsequently converted by the host cellular enzymes to the toxic 5-fluoro-UTP and 5-fluoro-dUMP metabolites. The incorporation of 5-fluro-UTP into RNA results in RNA dysfunction, 21 while 5-fluoro-dUMP suppresses thymidylate synthase, which ultimately inhibits DNA synthesis. 22 Additionally, 5-FU has a bystander killing effect due to the ability of 5-FU metabolites to diffuse to surrounding cells. 23 Thus, the firefly luciferase gene and the yCD gene were cloned in-frame with the 2A sequence in the context of the HSV-1 amplicon backbone vector.
The HSV-1 amplicon viral vectors are replication defective and nonintegrating vectors that are derived from HSV-1. The large DNA insert capacity of up to 150 kb of DNA makes it the most powerful and versatile gene delivery platform for carrying multiple reporter and therapeutic transgene cassettes simultaneously, including endogenous controlling elements that may prove critical to ensure prolonged, regulated and tissue-specific expression. Furthermore, because the HSV-1 amplicon viral vectors can be packaged in the absence of helper virus, and they typically contain only two noncoding elements of the HSV, ori s and pac, these vectors are therefore relatively noncytotoxic and nonpathogenic when administered in vivo. 24 We have independently confirmed this by injecting the amplicon viral vectors (1Â10 6 transduction units, TU) into immunocompetent BALB/c mice via the tail vein. 25 Thus, the HSV-1 amplicon vectors should serve well as potential carrier of therapeutic genes to HCC tumors.
In this study, we have demonstrated (i) the ability of FMDV 2A sequence to mediate the bicistronic gene expression of a therapeutic gene (yCD) and a reporter gene (luciferase) in the context of the HSV-1 amplicon viral vector; (ii) the regression of a primary human HCC tumor xenograft treated by a HSV-1 amplicon viral vector harboring the yCD therapeutic gene after 5-FC prodrug administration; and (iii) the possibility of monitoring therapeutic gene expression by firefly luciferase using a noninvasive bioimaging system to confirm that treatment is supported by the delivery of the therapeutic gene.
RESULTS

Bicistronic expression of luciferase reporter gene and yCD mediated by FMDV 2A
In order to monitor the therapeutic gene expression in vivo, the firefly luciferase reporter gene was cloned in frame with the yCD gene via the 2A autoprotease sequence from FMDV ( Figure 1a ). This 20 aminoacid FMDV 2A sequence has been reported to mediate self-processing through a proposed ribosomal-skip mechanism, resulting in two translation products. 18, 26 We first examined the functional expression and stability of proteins conferred by pHGCX-L2C in vitro. Human HCC cells, PLC/PRF/5 cells, were transfected with the pHGCX-L2C plasmids and control plasmid pHGCX-Luc. Cell lysates were harvested at various time points post-transfection. The results showed that the expression of Luc proteins correlated with those of yCD proteins. However, luciferase proteins diminish faster in comparison to yCD proteins (Figure 1b) . To further determine whether this may be due to a difference in the half-life of these two proteins, the experiment was repeated with cells transfected with pHGCX-Luc as control. For better visualization of protein expression, only half of the amount of cell lysates was used. Similar results were obtained in that luciferase protein expression mediated by pHGCX-L2C amplicon vectors declined rapidly at day 3 (Supplementary Figure S1) . By contrast, luciferase proteins could be detected at both day 3 and day 5 in cells transfected by pHGCX-Luc vectors, suggesting that the short 2A peptide that remains fused to the C-terminus of the 'upstream' luciferase protein could have affected, albeit minimally, the stability of the proteins. This was confirmed from measuring the luciferase reporter activities in cells transfected separately with pHGCX-Luc and pHGCX-L2C plasmids. The level was lower in the latter although the difference was not statistically significant (P40.05; Figure 1ci In vitro cell kill efficiency of the HGCX-L2C amplicon viral vector The pHGCX-Luc and pHGCX-L2C amplicon plasmids were first packaged into infectious HSV-1 amplicon viral vector using the helper virus-free method. PLC/PRF/5; HuH-7 (HCC cells), and DGli36; A549 (non-HCC cells) were infected with HGCX-L2C or control viral vector HGCX-Luc. Effective cell killing mediated by the HGCX-L2C amplicon viral vector in the presence of 1-10 mM of 5-FC was observed with all HCC and non-HCC cells tested in this study, as shown in Figure 2 . No significant amount of cell death was observed when these cells were infected with control viral vector HGCX-Luc even in the presence of high concentration of 5-FC at 10 mM.
Next, we asked whether HSV-1-based amplicon vector remained as the vector of choice for patient-derived primary HCC. These cells were derived from primary HCC tissues (histological grade 3), which were serially transplanted into immunocompromised severe combined immunodeficiency (SCID) mice. 27 For this purpose, we compared the infectibility of HSV-GFP (HSV-green fluorescent protein) (basic HSV-1 amplicon viral vector expressing GFP regulated by HSV-1 IE 4/5 promoter) with Ad-GFP (Ad expressing GFP regulated by cytomegalovirus (CMV) promoter) and Lenti-GFP (second generation lentivirus expressing GFP regulated by CMV promoter). In order to compare the infectibility of different viral vectors, virus titration method was standardized by using 2-2 cells in TU ml -1 as described in Materials and Methods. This was followed by infecting the HCC 26-1004 cells at multiplicity of infection (MOI) of 1.0. The number of GFP-positive cells in HSV-GFP and Ad-GFP were counted after 24 h post-infection. For Lenti-GFP, cluster of GFP-positive cells were counted after 48 h post-infection. As shown in Figure 3a , the HSV-1 amplicon viral vector outperformed other types of viruses. The HSV-1 amplicon viral vector was threefold and twofold more efficient in transducing the primary HCC cells when compared with Ad and lentivirus, respectively. The difference was highly significant when the relative infectivity of HSV-1 vector was compared with Ad and lentivirus by Student's t-test (Po0.0005) and among the different vector types by one-way analysis of variance (overall F¼271.7; Po0.0001).
The in vitro cell killing efficiency of these primary HCC cells was further confirmed using cell viability assay. Primary HCC cells were infected with the HGCX-L2C amplicon viral vector at MOI of 1 and 2 in the presence of 2 mM 5-FC (Figure 3b ). Effective cell kill was observed at day 7 with o20 and 10% viable cells in the experimental group infected with MOI 1 or 2 of HGCX-L2C, respectively.
The HGCX-L2C HSV-1 amplicon viral vector was further characterized in vivo by intratumoral injection of 1.5Â10 6 TU of HGCX-L2C into HCC 26-1004 primary HCC xenograft models in SCID mice, whereas control tumors were injected with Hanks' balance salt solution (HBSS) (Figure 3c ). High luciferase activities were detectable in representative mice injected with HGCX-L2C at day 5. The functional expression of yCD was confirmed by analyzing the tumors using western blot analysis (Figure 3d ). Taken together, 
-test).
The differences analyzed using one-way analysis of variance were also highly significant (overall F¼271.7; Po0.0001). Post hoc test using the Tukey's multiple comparison also revealed that the differences between the relative infectivity with the different vector types were highly significant (Po0.001) for HSV-GFP versus Ad-GFP, and also for HSV-GFP versus Lenti-GFP. For Ad-GFP versus Lenti-GFP, the calculated P-value was o0.01. characterization results indicate that the FMDV 2A-mediated bicistronic expression of Luc and yCD could facilitate the monitoring of yCD therapeutic gene expression in vivo by imaging luciferase activity noninvasively.
In vivo therapeutic efficacy of the HGCX-L2C amplicon viral vector on primary HCC Next, the therapeutic efficacy of HGCX-L2C amplicon viral vectors was determined by an intratumoral administration of the viral vectors (1.5Â10 6 TU per mouse; n¼5 per group) into pre-established subcutaneous primary HCC mouse xenograft (Figure 4a) . The mice were then divided into two groups. One group received an intraperitoneal (i.p.) injection of 5-FC, while the other group received similar volume of phosphate-buffered saline (PBS). Similar procedure was performed in another two groups of HCC-tumor bearing mice injected with HBSS. Anti-tumor effect was observed in the group of mice treated with HGCX-L2C and 5-FC. At day 20, the mean tumor volume of mice treated with both viral vector and prodrug (94 ± 3 mm 3 ) was 8.9-fold smaller compared with the control group injected with similar viral dosage and PBS (837±89 mm 3 ). The control group injected with HBSS and 5-FC also showed partial tumor regression, which may be due to the cytotoxic effect of the prodrug. Mice injected with viral In vivo imaging of yCD expression in primary HCC KC Sia et al vector and PBS showed similar tumor growth kinetics to the control tumor group with HBSS and PBS. Although HGCX-L2C induced an efficient anti-tumor response, the luciferase reporter activities were diminished to barely detectable levels at day 17 post-injection (Figures 4b and c) . This was not surprising considering that the amplicon vectors are defective in replication. Based on a one-time injection, the 89% of tumor regression must be, in part, attributed by the bystander effect of 5-FU. To confirm that tumor regression was truly due to the cytotoxic and bystander effect of 5-FU and not to that of 5-FC, we established SCID mice harboring bilateral primary HCC tumors of similar size. HGCX-L2C amplicon viral vectors were injected to only one of the two tumor nodules, while the other was injected with similar volume of HBSS. Both tumor nodules on the mouse were exposed to 5-FC as injected via i.p. route (Figure 4d ). After 17 days of treatment, tumors injected with the HGCX-L2C amplicon viral vector were considerably smaller compared with adjacent tumors that were injected with HBSS. In fact, the HGCX-L2C-treated tumors were regressing, whereas the untreated tumors grew larger in volume. Noninvasive luciferase imaging indicated expression of the Luc gene (or the yCD gene) in treated tumors. When both tumor nodules were harvested and analyzed at day 17, the control tumors were highly vascularized, while the treated tumors were correspondingly less bloody and smaller in size.
For these viral vectors to be of clinical relevance, they would need to be administered systemically instead of intratumorally. For this purpose, we generated a liver orthotopic PLC/PRF/5-DsRed2 tumor model in SCID mice by subcapsular injecting 5Â10 6 PLC/PRF/5-DsRed2 cells into the left lateral liver lobe using a 27-G needle. After 1 month, PLC/PRF/5-DsRed2 tumors were established in liver as shown in Figure 5a . The mice harboring the orthotopic PLC/PRF/5-DsRed2 tumors were then systemically tail vein injected with 3Â10 6 TU HGCX-L2C HSV-1 amplicon viral vector in 100 ml HBSS. After 24 h post-injection, the distribution of viral vector in liver versus tumor region was examined. Using a dual-color bioimaging system, the results showed that luciferase activities were located throughout the liver region, and some were localized in the DsRed2-positive tumor regions (as regionally outlined in white, Figure 5b ). Normal liver and DsRed2-positive tumors were harvested separately and the copy number of Luc-encoding vector DNA and luciferase reporter activities were determined (Figures 5c and d, respectively) . The results obtained were consistent with the noninvasive imaging results in that the luciferase gene copy number found in the liver was about 2.1-fold higher as compared with the tumor region (Figure 5c ) and the luciferase activity found in the liver was also 1.8-fold higher in the normal compared with the tumor region (Figure 5d ). Very little luciferase activity was detected in other organs. Using noninvasive bioimaging system, we have demonstrated that basic HSV-1 amplicon vector can be efficiently delivered to orthotopically implanted HCC systemically; it is therefore possible to further develop these vectors for potential treatment of HCC.
DISCUSSION
Clinical translation from animal models has been challenged by the complex in vivo physiological conditions and the heterogeneous state of the primary tumor cells. The level of viral vector-mediated transgene expression is known to be affected by host cellular factors that vary from cell to cell; viral or exogenous elements from mammalian or bacterial origins; and immune responses that may arise from the amplicon infection. [28] [29] [30] In an attempt to better understand the strength and duration of the therapeutic gene expression, we constructed a bicistronic 2A-mediated reporter/therapeutic gene expression cassette that allow real-time in vivo monitoring of therapeutic gene expression noninvasively through imaging of the reporter luciferase gene. With this strategy, the expression of the therapeutic gene can be efficiently optimized for improved and enhanced in vivo cancer treatment.
The FMDV 2A system is used to drive the bicistronic gene expression as the sequence is short (57 bp) and the levels of gene transcription of both genes should be similar when compared with IRES. Overall, the results showed that the expression of the second gene followed those of the first, although they were quantitatively dissimilar (Figures 1b and ci) . When two different genes are linked using 2A peptide sequence, about 18 amino acids are left on the C-terminus of the first gene and a single proline residue remains on the N-terminus of the second gene. 31 While the N-terminal addition of the single proline to the second gene does not appear to cause problems, 32 the longer C-terminal extension on the upstream protein could potentially interfere with post-translational modification; trafficking or function; or inducing an immune response that could limit protein half-life in vivo. 33, 34 In our study, we found that the expression of luciferase proteins in cells transfected with pHGCX-Luc was higher than those transfected with pHGCX-L2C (Supplementary Figure S1) . The observation is similar to those reported by Lengler et al. 33 in that hrGFP-2A protein becomes more unstable than hrGFP protein in HEK293 cells transfected with the two constructs. The observed difference in the levels of luciferase protein expressions could also be attributed by the smaller size pHGCX-Luc vector construct when compared with pHGCX-L2C, thus resulting in differences in transfection efficiency, which was not determined.
Despite the slight difference, we have nevertheless found that the 2A peptide approach is informative in providing an indication to the strength and duration of the therapeutic gene in preclinical mouse xenograft models. For example, at day 17, when luciferase activities were hardly detectable, the yCD level should be correspondingly low (Figures 4b and c) . This would serve as a good indication to follow-up with a second viral dose if necessary. In the current study, we have injected only one dose of amplicon viral vectors at 1.5Â10 6 TU per mouse, and observed significant tumor reductions (Figure 4a ). It may be worth noting that we have observed a higher than anticipated cytotoxicity induced by the group of mice injected with HBSS and 5-FC (Figure 4a ). This could be due to the high level of 5-FC administered, at 2000 mg kg -1 per day for a total of 17 days. By contrast, others have found that 5-FC treatment has no effect on the weight or survival of the mice when administered at 400 mg kg -1 per day for 9 days. 35 Using a bilateral tumor model system, we were able to confirm that the tumor regression was truly mediated by the viralmediated yCD expression as indicated by the luciferase activity, and not from the side effect of high dose of 5-FC since both tumor nodules were exposed to similar level of 5-FC (Figure 4d ). In the orthotopic HCC mouse model, the results showed that amplicon viral vectors could be systemically delivered to the DsRed2-positive tumor site (Figure 5b) . Because of the ubiquitous CMV promoter, luciferase activities could be detected in both normal murine hepatocytes and human HCC cells (Figure 5b) . The luciferase gene copy number was found to be correspondingly higher in the normal murine liver when compared with tumor ( Figure 5c ). It is possible that the liver matrix proteins that modulate viral entry are different for murine liver versus HCC. Thus, a higher fraction of murine hepatocytes is infected. However, in vitro infectivity study with HGCX-L2C at MOI 1.0 revealed that the primary mouse hepatocytes were about sevenfold less infectable when compared with HCC (Supplementary Figure S2a) . Thus, the higher luciferase activities in the normal part of the mouse liver when compared with the HCC tumor region is unlikely to be due to differential infectivity of HGCX-L2C viral vectors. Rather, our latest findings suggest that there are some unknown barriers that impede the vectors from reaching the tumor regions when the vectors are administered via intravenous injection. We demonstrated that with sixfold less input of total HGCX-L2C viruses, there was B14-fold higher level of luciferase activities detected when the viruses were intratumorally administered when compared with intravenous injection (Supplementary Figure S2b) . We are uncertain what might be the factors that prevented viral entry following systemic administration. It is possible that the HCC tissue architecture is likely to have fibrotic areas; 36 high interstitial tumor fluid pressure, 37 which prevented effective viral infection and spreading. Additional experiments will be required to discriminate among these possibilities.
The yCD gene is capable of conferring an effective bystander effect whereby the significant elimination of tumor cells can be achieved via the passive diffusion of 5-FU from no more than 10% of the yCDpositive cells. 38 This is consistent with our observations in that as low as 3.3% yCD expressing cells were capable of killing 50% of the total cancer cell population (Figure 1d) . Likewise, others have reported that 2% of CD transduced cells can produce a significant tumor reduction in vivo. 38 In the setting of a highly vascularized tumor, transduction of neighboring tumor endothelial cells would lead to the destruction of blood vessel and curtails tumor growth. 28 However, a recent report suggests that tumor-derived endothelial cells are biologically different from normal endothelial cells in that they have acquired greater resistance to 5-FU. 39 Thus, it is anticipated that the transduction of tumor-derived endothelial cells may enhance the bystander effect by delivering more 5-FU to the tumor cells. This could explain the observation by Ram et al. 40 whereby researchers reported that b-galpositive endothelial cells were detected in the intracerebral 9 l glioma mouse model, which was indicated to enhance the therapeutic efficacy. It is therefore not surprising that some groups of researchers have intentionally modified the normal cells surrounding the tumor cells in an attempt to enhance the therapeutic efficacy. 41, 42 Nevertheless, the precise mechanism and effect of 5-FU on tumor versus normal endothelial cells is not well defined and may warrant additional studies.
From our results, we have demonstrated that the activities of HGCX-L2C could be monitored in HCC xenograft mouse model. The overall efficiency of therapeutic genes may be enhanced by employing the fusion of yCD with yeast uracil phosphoribosyltrans-ferase gene, or the yCD-YUPRT. 43 The bifunctional chimeric gene protein products has been shown to be 1000-fold more potent than cytosine deaminase by itself. 44 The enhanced potency is due to a more efficient conversion of the 5-FU into 5-fluoro-UMP. Enhanced efficacy has also been shown by the fusion of yCD to the HSV-1 tegument protein (VP22), which increases the spread of the fusion proteins to surrounding recipient cells. 45, 46 Besides the genetic manipulation of the therapeutic gene, one can also improve on the stability of the viral vectors by the incorporation of nonintegrating episomal elements such as the EBNA-1/oriP system, 47, 48 or the employment of a replication-competent HSV-1 viruses. Nakamura et al. 49 demonstrated that such a mutant virus that expressed the yCD had greater therapeutic effect than the oncolysis induced by the viral replication alone. The later development in the field of gene-directed enzyme prodrug therapy includes infecting neural stem/progenitor cells or mesenchymal stem cells with viral vector that carry the yCD gene. [50] [51] [52] These cells possess intrinsic tumor tropic capacity and may serve as suitable delivery vehicles for cancer treatment.
From our study, we have also observed B5-10% of viable cells postviral infection in the case of HuH-7 ( Figure 2 ) and primary HCC cell (Figure 3b ). This could suggest a possible resistance population although we did not analyze the residual tumor for the presence of CD133; CD90; ABCG2; c-Met and EpCAM, which have been implied as potential markers for liver tumor initial cells. 53 Alternately, the residual viable cells may represent the rapid development of acquired resistance against 5-FU. Interestingly, Jin et al. 54 showed that 5-FU resistant HCC tumor cells also exhibited resistance to Dox and cytarabine but not vincristine, taxol, cisplatin and hyroxycamtothecine. The resistance was attributed to overexpressed thymidylate synthase and multidrug resistance-associated proteins, as well as enhanced levels of intracellular glutathione content and total glutathione S transferases activities. Based on these findings, we speculate that strategies employed to further increase the levels of yCD or the generation of superCD, 55 yCD-YUPRT may not be effective against the resistance cells. Rather, the combination therapy approach that targets multiple signaling pathways simultaneously may be a better way for future therapy design. For example, sorafenib is an orally active tyrosine kinase inhibitors that target the vascular endothelial growth factor receptors, the platelet-derived growth factor receptor b, the FMS-like tyrosine kinase 3 (Flt-3), c-kit protein and RET receptor tyrosine kinases. 56 Another chemotherapy drug that has been used for the treatment of HCC is a mitotic inhibitor (Paclitaxel) that binds to the N-terminal domain of b-tubulin. 57 The formation of the microtubulepaclitaxel complex prevents microtubule disassembly, which in turn leads to the inhibition of spindle formation in cells undergoing mitosis.
Other possible strategy one could consider to improve the therapeutic efficacies mediated by HGCX-L2C amplicon viral vectors would be to include radiation as 5-FU has been known to serve as a radiosensitizer agent. 58 We have recently demonstrated that luciferase expression mediated by HSV-1 amplicon viral vectors are minimally affected, the vectors are still fully functional in the presence of radiation and chemotherapy. 59 For potential clinical application, HCC-specific promoter will also be a valuable asset to minimize undesirable side effect arising from nonselective therapeutic viral vectors. Recently, Foka et al. 60 had identified novel HCC-specific promoters that could be incorporated into the HSV-1 vector platforms for efficient transgene expression in HCC.
In summary, we have demonstrated the feasibility of monitoring the expression of yCD in HCC patient-derived xenograft mouse model by fusing the luciferase reporter gene with the prodrug activation gene. Although firefly luciferase reporter gene may not be compatible with clinical gene therapy trials, it is nevertheless an efficient reporter gene to monitor the activity and biodistribution of therapeutic gene expression in preclinical gene therapy animal studies. These results can be informative to improve the safety and efficacy of the viral dosage for potential clinical applications. Using this method, the true efficacy of a therapeutic gene can be accurately monitored and the strategy can be developed for potential enhanced treatment against HCC.
MATERIALS AND METHODS
Cell lines
A human HCC cell line (PLC/PRF/5) and a human lung adenocarcinoma cell line (A549) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). A human HCC cell line (HuH-7) was obtained from the Japanese Collection of Research Bioresources (JCRB cell bank, Osaka, Japan). Human DGli36 glioma cells (also known as Gli36qEGFR), which were kindly provided by Ichikawa T and Chiocca EA (Ohio State University Medical Center, OH, USA). African green monkey kidney 2-2 cells were derived from Vero cells that constitutively expressed the HSV-1 ICP27 proteins (kindly provided by Sandri-Goldin RM, University of California, Irvine, CA, USA). All cells were maintained at 37 1C in a 5% CO 2 -95% air atmosphere and cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT, USA), penicillin (100 U ml -1 ; Invitrogen, Grand Island, NY, USA), streptomycin (100 mg ml -1 ; Invitrogen) and 2 mM L-glutamine (Invitrogen). The DGli36 cells were further supplemented with 1 mg ml -1 puromycin (Invivogen, San Diego, CA, USA), while the African green monkey kidney cells were cultured in the presence of 500 mg ml -1 of Geneticin (Invitrogen).
HSV-1 amplicon plasmid DNA constructs
The generation of pHGCX-Luc has been previously described. 61 For the construction of pHGCX-L2C, firefly luciferase and yCD genes were cloned in frame with the FMDV 2A sequence. The firefly luc gene was first extracted by polymerase chain reaction (PCR) from pHGCX-Luc without a stop codon, using a forward primer introducing an XhoI cut site (5¢-CTCGAGCCACCATG GAAGACG-3¢) and the reverse primer (5¢-CACGGCGATCTTTCCGCCCTTC-3¢). The 1.7-kb PCR product was then purified using the QIAquick PCR Purification Kit (Qiagen, Valencia, CA, USA) and subjected to T4 polynucleotide kinase treatment before being blunt end ligated with mung bean nuclease and a calf intestinal alkaline phosphatase treated 2.9 kb 2A-yCD fragment, released from pMGMT-2A-yCD (4.9 kb) using the XhoI restriction enzyme, to generate the pLuc2ACD vector. The 2.2-kb bicistronic cassette containing Luc-2A-yCD (L2C) in pLuc2ACD can be released using the XhoI and NheI cut sites and subcloned into pHGCX (kindly provided by Chiocca EA, Ohio State University Medical Center) using the XhoI and XbaI sites (which produce ends compatible with NheI) to generate pHGCX-L2C. The DNA construct pMGMT-2A-yCD was previously generated by first releasing the 1.2-kb MGMT-2A fragment from MGMT-2A-GFP 62 (8.1 kb) using the EcoRI restriction enzyme. The MGMT-2A fragment was then treated with mung bean nuclease and subcloned into the nuclease treated, linearized, NcoI digested pORF-Fcy (which contained the yCD gene; Invivogen) to generate pMGMT-2A-yCD. All enzymes were purchased from NEB, Beverly, MA, USA.
Luciferase reporter gene assay
The cells used were harvested following transfection and lysed in 120 ml lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 1% Triton X-100). Luciferase activity and protein concentration were measured as described previously. 61 
yCD enzymatic assay
Cells were washed twice with PBS, resuspended in PBS at a concentration of 5Â10 5 cells per 100 ml PBS, and exposed to five cycles of thawing/freezing. A total of 50 ml of each sample was mixed with 950 ml of a 3-mM solution of 5-FC in PBS and incubated at 37 1C. At different time points, 50 ml samples were collected and quenched with 950 ml of 0.1 mM HCl. The concentrations of 5-FU and 5-FC for each condition were determined spectrophotometrically 62 using the following formulas: 5-FC (mM)¼0.119(A 290 )À0.025(A 255 ); 5-FU (mM)¼0.185(A 255 )À0.049(A 290 ). Each experiment was performed independently three times. CD activities (U mg -1 ) were calculated. One unit (U) of CD activity was defined as the amount of enzyme releasing 1 mmol of 5-FU per minute under standard assay conditions at 37 1C.
Cell viability assay
Cell viability was assayed with the cell counting kit-8 (CCK-8, Fluka, Buchs, Switzerland). For a 96-well plate, 100 ml of cell suspension containing 1Â10 4 cells was seeded per well, whereas for a 24-well plate, a total of 1Â10 5 cells in 600 ml cell suspension were seeded per well. After incubation for 24 h at 37 1C, 5% CO 2 , these cells were transfected by 0.6 mg plasmids (in 24-well plate only) or infected by viral vectors at appropriate MOI (that is, MOI 1.0 for HuH-7 and DGli36, MOI 8.0 for PLC/PRF/5 and MOI 10 for A549) for 6 h and replenished with fresh complete medium with or without 2 mM of 5-FC. To assay for cell viability after a certain amount of treatment time, 10 ml (for a 96-well plate) or 60 ml (for a 24-well plate) of CCK-8 solution was added to each well and the plate was incubated for another 2-4 h at 37 1C, 5% CO 2 . The absorbance was then read at 450 nm with a reference at 650 nm using a Victor 3 V plate reader (Perkin-Elmer Life Sciences, Waltham, MA, USA).
Helper virus-free packaging
In all, 2-2 cells (3Â10 6 cells) were co-transfected with amplicon DNA and a set of five overlapping cosmids that represent the entire HSV-1 genome but lack the pac signal 63 using Lipofectamine (Invitrogen) and Plus reagent (Invitrogen), as instructed by the manufacturer. Details of the methodology have been previously described. 64 To determine vectors titers (TU per milliliter or TU ml -1 ), 2-2 cells were infected and green fluorescent cells were counted under a Nikon Eclipse TE300 inverted fluorescence microscope (Nikon, Tokyo, Japan) after 24 h.
Western blot analysis
PLC/PRF/5 cells (3Â10 5 cells in six-well plate) were transfected with 3 mg of pHGCX-L2C plasmid using 8 ml of Lipofectamine (Invitrogen) and 5 ml of Plus reagent (Invitrogen), according to the manufacturer's instructions. The cells were harvested at days 1, 3, 5 and 7 following transfection and lysed in 120 ml lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 1% Triton X-100). Protein lysates (100 mg) were then separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotted with rabbit anti-luciferase polyclonal antibody (1:1000; 0.2 mg ml -1 ; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or sheep anti-yCD polyclonal antibody (1:1000; 5 mg ml -1 ; Abcam, Cambridge, MA, USA) overnight at 4 1C. The polyvinylidene fluoride membrane was then incubated in blocking buffer (5% nonfat milk in PBS containing 0.1% Tween 20) containing secondary goat anti-rabbit immunoglobulin horseradish peroxidase-conjugated antibodies (1:2000; DakoCytomation, Glostrup, Denmark) or rabbit anti-sheep immunoglobulin horseradish peroxidaseconjugated antibodies (1:2000; Chemicon, Temecula, CA, USA) for 1 h at room temperature. The membrane was then subjected to an enhanced chemiluminescence reaction using a Western Lightning chemiluminescence reagent plus kit (Perkin-Elmer Life Sciences) for 1 min before being exposed on film in the M35 X-OMAT Processor (Kodak, Rochester, NY, USA). The blot was reprobed with mouse anti-human actin monoclonal antibody (1:10 000; 0.2 mg ml -1 ; NeoMarker, Fremont, CA, USA). For tumor samples, about 100 mg of tumor tissue was harvested and minced with scissors in 0.6 ml homogenization buffer (250 mM sucrose, 2 mM EDTA, 10 mM Tris-Cl, 1 mM phenylmethylsulfonyl fluoride (PMSF)). The samples were then subjected to mechanical homogenization for 30 s followed by three freeze/thaw cycles in liquid nitrogen, a 37 1C water bath, and 14 K r.p.m. centrifugation before being subjected to western blot analysis.
Establishment of primary patient-derived (HCC 26-1004) and PLC/PRF/5-DsRed2 tumor xenografts HCC 26-1004 tumors were derived, with informed consent, from patients undergoing liver resectioning and histology analysis with confirmed diagnoses of HCC. 27 Detail procedure for the establishment of HCC 26-1004 in SCID mice was described previously. 47 Single cell suspensions were prepared by gently disrupting the tumors with fine forceps in the presence of 0.5 mg ml -1 collagenase (type IV, pH 7.5; Sigma, St Louis, MO, USA). Procedure to isolate the single cell suspension was performed according to Pichard et al. 65 For the establishment of PLC/PRF/5-DsRed2 tumor xenograft, five million of the cells were resuspended in 20 ml of PBS and subcapsularly injected into the left lateral liver lobe of 6-week-old female SCID mice by using a 27-G needle. After 1 month, the mice were then tail vein injected with 3Â10 6 TU of HGCX-L2C HSV-1 amplicon viral vector.
Animal work
All animal experiments were performed according to the guidelines and protocols approved by the SingHealth Institutional Animal Care and Use Committee, Singapore. After 4 days of HCC 26-1004 tumor inoculation, 1.5Â10 6 TU of viral vectors in 100 ml HBSS were injected intratumorally (n¼5) and followed by i.p. injection of 5-FC at a 1000 mg kg -1 dose, twice a day. At various designated time points, tumor volumes were quantified with calipers, using the formula V (volume)¼p/6Â(LÂ(W) 2 ), where L is length and W is width. At the same time point, mice were subjected to noninvasive bioluminescence imaging using the Xenogen IVIS Lumina (Caliper Life Sciences, Hopkinton, MA, USA) system. For all bioluminescence imaging, mice were first i.p. injected with 0.17 mg g -1 body weight D-luciferin (Caliper Life Sciences) in PBS. Five minutes later, mice were anesthetized and kept warm on a 37 1C isothermal pad. After 20 min after i.p. injection of D-luciferin, bioluminescence images were acquired at 10 min of exposure time, binning at 4 and f/stop at 1. For DsRed2 imaging, red fluorescence signal from orthotopic PLC/PRF/5-DsRed2 tumors were acquired with DsRed2 filter set at 30 s of exposure time, binning at 1 and f/stop at 4. All image analysis and bioluminescence signal quantifications were performed using Living Image software version 3.0 (Caliper Life Sciences). Regions of interest were defined by 1.2 cm circle. Background photon flux was defined from an region of interest drawn over the regions on mice where no vector had been administered.
Vector genome copy number analysis
Orthotopic PLC/PRF/5-DsRed2 tumor and its match liver were harvested after the imaging. The samples were then ground in liquid nitrogen with mortar and pestle. Whole cellular DNA was extracted using the QIAamp DNA mini kit (Qiagen) according to the manufacturer's instruction with RNase treatment. The DNA samples were then subjected to quantitative PCR analysis to determine the vector genome copy number as described previously 47 using a Rotor-Gene Q real-time PCR system (Qiagen) with QuantiTect SYBR Green PCR Kit (Qiagen).
Statistical analysis
Data are presented throughout this study as mean values ± standard error of the mean (s.e.m.). Statistical significance was determined by an unpaired t-test, and values of Po0.05 were considered significant.
